Simon serves as chief executive officer of Curie Therapeutics. He is founder, president and a member of the Board of Directors.
Before joining Curie Therapeutics, Simon was entrepreneur-in-residence at Atlas Venture. Prior to this, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Simon brings to Curie more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most widely used drugs in the industry including Rituxan® and Actemra®. Simon is a Fellow of the Royal Society of Medicine, Board member of an RA Capital Management Stealth Company and Scientific Advisory Board member of Q32 Bio. He obtained his Ph.D. from University of Hertfordshire and studied Physiology at the University of Manchester in the UK. Simon is well published, having authored over 50 peer reviewed articles and patents.